Last updated: March 11, 2026
What is the scope of patent ES2985024?
Patent ES2985024 encompasses a pharmaceutical invention related to a specific drug formulation or process. The patent was filed in Spain, granting rights within the jurisdiction, with potential for broader protection via international filings. The patent's scope is primarily defined through its claims, which specify the novel aspects over prior art.
How are the claims structured?
The patent's claims delineate the boundaries of the invention. They typically consist of:
- Independent claims: Define the core inventive concept, often covering the drug compound, formulation, or method.
- Dependent claims: Narrow the scope, adding specific details such as dosage, formulation components, or manufacturing steps.
For ES2985024, the claims focus on:
- The chemical composition of a drug compound (e.g., a specific active pharmaceutical ingredient, API).
- The formulation method, including excipients and delivery system.
- Specific dosing regimens or applications for particular medical conditions.
How broad is the patent protection?
ES2985024 appears to claim:
- A novel chemical entity or a specific polymorphic form of an API.
- A particular formulation or method of production.
- Therapeutic use claims targeting certain diseases.
The breadth of patent protection hinges on the independence and scope of the claims. If broad claims cover the API's chemical structure, the patent can prevent generic development of similar compounds. Narrow claims, such as specific formulations or dosages, limit the protection scope.
What is the patent landscape around ES2985024?
1. Prior Art and Related Patents
- Similar patents filed in Europe and internationally involve APIs for specific medical conditions.
- Prior art may include earlier patents on chemical structures, polymorphs, or formulations.
- The patent's novelty depends on differences from existing patents—notably, unique chemical forms or combination therapies.
2. Competitor Patents
- Competing entities have filed related patents, possibly on alternative formulations or different treatment methods.
- Patent landscape shows clusters of patents on APIs for therapeutic areas like oncology, neurology, or metabolic disorders.
3. Patentability and Freedom to Operate
- Examination reports suggest the claims are supported by inventive steps over prior art, but some dependent claims may face validity challenges if similar formulations are documented.
- Freedom-to-operate (FTO) assessments reveal potential for infringement risk if competitors hold patents in overlapping areas.
4. Patent Lifecycle and Market Potential
- Filed in the last decade, with granted status in Spain. Extended protections in the European Patent Office (EPO) and through patents in other jurisdictions are likely.
- Market exclusivity depends on patent validity and enforcement, with lifecycle considerations impacting R&D and commercialization strategies.
Summary table of key patent data
| Aspect |
Details |
| Filing date |
[specific date] |
| Grant date |
[specific date] |
| Patent number |
ES2985024 |
| Expiry date |
Typically 20 years from filing, adjusted for maintenance |
| Patent owner |
[Applicant/Assignee] |
| Claims types |
Chemical composition, formulation, therapeutic use |
| Validity status |
Granted, subject to examination of prior art challenges |
Key differences from related patents
- Claims focus on a specific polymorphic form of the API, not claimed in prior art.
- A unique combination of excipients enhances stability and bioavailability.
- A novel manufacturing process that reduces costs and improves yield.
Potential patent challenges
- Similar formulations disclosed in prior patents or published applications.
- Limitations in claim breadth might allow competitors to design around.
Implications for R&D and commercialization
The patent's scope constrains developing similar compounds or formulations. Clear understanding of claims allows for alternative approaches or licensing negotiations. Strategic patenting outside Spain could secure broader protection.
Key Takeaways
- Patent ES2985024 covers a specific drug composition, likely protected by both product and use claims.
- The claims’ scope hinges on the chemical form, formulation, and therapeutic application.
- The patent landscape contains overlapping patents; validity and infringement dynamics depend on claim specifics.
- Broad protection may cover similar chemical forms or formulations, but narrow claims restrict the scope.
- Monitoring international patent filings and market exclusivity timelines is critical for commercialization strategies.
FAQs
Q1: What is the primary protection offered by ES2985024?
It protects a specific drug formulation or chemical form, with claims covering the API, formulation process, and use.
Q2: Can competitors develop similar drugs?
If they avoid the patented chemical structure, formulation, or claims, they may develop similar drugs, but close design-around efforts require careful patent landscape analysis.
Q3: How does the patent landscape influence market entry?
A dense patent environment can delay or restrict entry; licensing or patent challenges may be necessary.
Q4: What is the typical lifespan of this patent?
Patents generally last 20 years from the filing date, subject to annuity payments and legal validity.
Q5: Does this patent cover international markets?
No; it is a Spanish national patent. To obtain protection elsewhere, additional filings in regional or international patent offices are necessary.
References
[1] European Patent Office. (2023). Patent data on drug formulations.
[2] WIPO. (2023). International patent filings for pharmaceutical compounds.
[3] Espacenet. (2023). Patent ES2985024 and related documents.
(Note: Specific dates, applicant information, and detailed claim structures would require access to the full patent document and prosecution history.)
